Selection of Reference Genes for Normalization of Gene Expression Data in Blood of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (MJD/SCA3) Subjects.


Journal

Journal of molecular neuroscience : MN
ISSN: 1559-1166
Titre abrégé: J Mol Neurosci
Pays: United States
ID NLM: 9002991

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 31 01 2019
accepted: 27 06 2019
pubmed: 10 7 2019
medline: 21 4 2020
entrez: 10 7 2019
Statut: ppublish

Résumé

Alongside with the emergent clinical trials for Machado-Joseph disease/Spinocerebellar ataxia type 3 (MJD/SCA3) comes the need to identify molecular biomarkers of disease that can be tracked throughout the trial. MJD is an autosomal dominant neurodegenerative disorder caused by expansion of a CAG repeat in the coding region of the ATXN3 gene. Previous findings indicate the potential of transcriptional alterations in blood of MJD patients as biomarkers of disease. Accurate quantification of gene expression levels by quantitative real-time PCR (qPCR) depends on data normalization, usually performed using reference genes. Because the expression level of routinely used housekeeping genes may vary in multiple biological and experimental conditions, reference gene controls should be validated in each specific experimental design. Here, we aimed to evaluate the expression behavior of five housekeeping genes previously reported as stably expressed in peripheral blood of patients from several disorders-peptidylprolyl isomerase B (PPIB), TNF receptor associated protein 1 (TRAP1), beta-2-microglobulin (B2M), 2,4-dienoyl-CoA reductase 1 (DECR1), and folylpolyglutamate synthase (FPGS). Expression levels of these five genes were assessed by qPCR in blood from MJD subjects (preataxic and patients) and matched controls. While all housekeeping genes, here studied, were stably expressed in our sets of samples, TRAP1 showed to be the most stable gene by NormFinder and BestKeeper. We, therefore, conclude that any of these genes could be used as reference gene in future qPCR studies using blood samples from MJD subjects.

Identifiants

pubmed: 31286408
doi: 10.1007/s12031-019-01374-0
pii: 10.1007/s12031-019-01374-0
doi:

Substances chimiques

HSP90 Heat-Shock Proteins 0
TRAP1 protein, human 0
beta 2-Microglobulin 0
cyclophilin B 137497-17-7
Oxidoreductases Acting on CH-CH Group Donors EC 1.3.-
2,4-dienoyl-CoA reductase EC 1.3.1.34
Cyclophilins EC 5.2.1.-
Peptide Synthases EC 6.3.2.-
folylpolyglutamate synthetase EC 6.3.2.17

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

450-455

Subventions

Organisme : Fundação para a Ciência e a Tecnologia
ID : SFRH/BD/121101/2016
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/DTP-PIC/0370/2012
Organisme : EU Joint Programme - Neurodegenerative Disease Research
ID : JPCOFUND/0002/2015

Références

J Alzheimers Dis. 2010;20(2):369-93
pubmed: 20164570
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Mov Disord. 2015 Jun;30(7):968-75
pubmed: 25914309
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
PLoS One. 2015 Nov 10;10(11):e0141853
pubmed: 26555275
Cerebellum. 2017 Dec;16(5-6):957-963
pubmed: 28699106
Neuromolecular Med. 2017 Mar;19(1):41-45
pubmed: 27246313
Eur J Neurol. 2008 Apr;15(4):371-6
pubmed: 18312406
BMC Mol Biol. 2008 May 06;9:46
pubmed: 18460208
J Huntingtons Dis. 2013;2(2):185-200
pubmed: 25063515
BMC Med Genomics. 2009 Aug 05;2:49
pubmed: 19656400
Biotechnol Lett. 2004 Mar;26(6):509-15
pubmed: 15127793
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Genet. 1994 Nov;8(3):221-8
pubmed: 7874163
J Biotechnol. 2004 Oct 19;114(1-2):121-4
pubmed: 15464605
Prog Neurobiol. 2012 May;97(2):239-57
pubmed: 22133674

Auteurs

Ana F Ferreira (AF)

Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal. ana.fb.ferreira@uac.pt.
Instituto de Investigação e Inovação em Saúde (I3S), Porto, Portugal. ana.fb.ferreira@uac.pt.
Instituto de Biologia Molecular e Celular (IBMC), Porto, Portugal. ana.fb.ferreira@uac.pt.

Mafalda Raposo (M)

Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
Instituto de Investigação e Inovação em Saúde (I3S), Porto, Portugal.
Instituto de Biologia Molecular e Celular (IBMC), Porto, Portugal.

João Vasconcelos (J)

Serviço de Neurologia, Hospital Divino Espírito Santo, Ponta Delgada, Portugal.

Maria do Carmo Costa (MDC)

Department of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

Manuela Lima (M)

Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
Instituto de Investigação e Inovação em Saúde (I3S), Porto, Portugal.
Instituto de Biologia Molecular e Celular (IBMC), Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH